Skip to main content
Explore URMC
menu

Projects

A Randomized Controlled Trial of the Rochester Forensic Assertive Community Treatment (FACT) Model in Minnesota

Funded by the Laura and John Arnold Foundation.  PI, J. Steven Lamberti, MD.  Co-Investigator, Robert L. Weisman, DO.   The Rochester FACT model is designed to prevent criminal recidivism and to promote recovery among justice-involved adults with schizophrenia and related disorders through mental health and criminal justice collaboration.  The aim of this study is to build upon previous research demonstrating feasibility and promise of the Rochester FACT model by replicating the model in Minneapolis-St. Paul.  This five-year study is being conducted in collaboration with the Minnesota Department of Human Services and the Minnesota Department of Corrections.

Project Publications

  • Lamberti JS, Weisman RL, Cerulli C, et al:  A randomized controlled trial of the Rochester forensic assertive community treatment model.  Psychiatric Services, 68:1016-1024, 2017
  • Lamberti JS:  Preventing criminal recidivism through mental health and criminal justice collaboration.  Psychiatric Services, 67:1206-1212, 2016
  • Lamberti JS, Russ A, Cerulli C, et al:  Patient experiences of autonomy and coercion while receiving legal leverage in forensic assertive community treatment.  Harvard Review of Psychiatry, 22:222-230, 2014
  • Lamberti JS, Deem A, Weisman RL, et al:  The role of probation in forensic assertive community treatment.  Psychiatric Services, 62:418 - 421, 2011
  • Lamberti JS, Weisman RL:  “Forensic Assertive Community Treatment:  Origins, Current Practice and Future Directions.  In:  Reentry Planning for Offenders with Mental Disorders: Policy and Practice.  Dlucacz, H, Ed.  Civic Research Institute, Kingston, NJ.   Chapter 7:1-24, 2010

The Effects of Neurofeedback on Social Information Processing

Funded by NARSAD.  PI, David Dodell-Feder, PhD.  Co-Investigator, J. Steven Lamberti, MD.  Recent research suggests that “theory of mind” (ToM) or one’s ability to attribute and reason about the beliefs, emotions, desires, and intentions of others, and its neural bases, is impaired in people with schizophrenia spectrum disorders (SSD). Further, the extent of impairment is associated with the extent of real-world social difficulties in SSD.  These findings suggest that targeting the neural network supporting ToM may lead to improvements in social functioning.  The aim of this project is to evaluate whether neurofeedback, delivered through real-time functional magnetic resonance imaging (rt-fMRI), impacts controlled engagement of the ToM neural network in people with schizophrenia.  

Project Publications

  • Dodell-Feder D, Tully LM, Hooker, CI: Social impairment in schizophrenia: New approaches for treating a persistent problem. Current Opinion in Psychiatry, 28(3), 236-242, 2015
  • Dodell-Feder D, DeLisi LE, Hooker CI:  The relationship between default mode network connectivity and social functioning in individuals at familial high-risk for schizophrenia. Schizophrenia Research, 156, 87-95, 2014
  • Dodell-Feder D, DeLisi LE, Hooker CI:  Neural disruption to theory of mind predicts daily social functioning in individuals at familial high-risk for schizophrenia. Social Cognitive and Affective Neuroscience, 9, 1914-1925, 2014.
  • Dodell-Feder D, Tully LM, Lincoln SH, Hooker CI:  The neural basis of theory of mind and its relationship to social functioning and social anhedonia in individuals with schizophrenia. NeuroImage: Clinical, 4, 154-163, 2014.
  • Dodell-Feder D, Koster-Hale J, Bedny M, et al:  fMRI item analysis in a theory of mind task. NeuroImage, 55, 705-712, 2011.

Diabetes Prevalence and Associated Risk Factors in Patients with Schizophrenia or Schizoaffective Disorder on Olanzapine or Clozapine

Funded by SMH Pilot Grant.  PI, Susanne Miedlich, MD.  Co-Investigators, Diana Fernandez, MD, PhD, MPH, J. Telva Olivares, MD, J. Steven Lamberti, MD.  Rates of type 2 diabetes are considerably higher in patients with schizophrenia compared to the general population. This risk is further increased by antipsychotic medications, especially olanzapine and clozapine which are most strongly associated with metabolic side effects.  Current recommendations for antipsychotic drug monitoring include a fasting plasma glucose and/or HbA1c but not an oral glucose tolerance test (oGGT).  However, both fasting plasma glucose and HbA1c have rather poor sensitivities in diagnosing diabetes, and close to 50% of cases may be missed using these tests when compared to oGGT. The aim of this study is to assess patients with schizophrenia or schizoaffective disorder who are on stable treatment with olanzapine or clozapine for prediabetes and Type 2 Diabetes.

Project Publications

  • Forrestel AC, Miedlich SU, Yurcheshen M, Wittlin SD, Sellix MT. Chronomedicine and type 2 diabetes: shining some light on melatonin. Diabetologia, 60:808-822, 2017
  • Lamberti JS, Olson D, Olivares T, et al:  Prevalence of the metabolic syndrome among patients receiving clozapine. American Journal of Psychiatry, 163:1273-1276, 2006
  • Goff DC, Sullivan LM, McEvoy JP, et al:  A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research; 80:45-53, 2005
  • Lamberti JS, Costea GO, Olson D, et al: Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates. Journal of Clinical Psychiatry, 66:900-906, 2005